Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

Tilgase, Andra; Grīne, Lita; Blāķe, Ilze; Borodušķis, Mārtiņš; Rasa, Agnija; Alberts, Pēteris

doi:10.1186/s13104-020-05068-4

Cited by 7 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that 50% of patients with CRC develop liver metastases [ 42 ]. The current treatments for SCLM include surgical resection, radiofrequency ablation, cryosurgery, hepatic arterial infusion and systemic chemotherapy [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Safety and long-term prognosis of simultaneous versus staged resection in synchronous colorectal cancer with liver metastasis: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Purpose The optimal time point for surgical resection of synchronous colorectal liver metastases (SCLMs) is still controversial. This meta-analysis evaluated the safety and long-term prognoses of simultaneous and staged resection of SCLM to provide a reference for clinical selection. Methods A systematic literature search for studies published by October 2022 was performed using PubMed, Web of Science, Embase, Scopus and Cochrane Library. The evaluated outcome parameters were total, gastrointestinal and hepatic complications, as well as perioperative mortality, intraoperative blood loss, total hospital stay, 5-year disease-free survival (DFS) and 5-year overall survival (OS). Results This meta-analysis included 22 nonrandomised and one randomised study comprising 4862 patients. The patients undergoing simultaneous resection of SCLM had similar total (OR = 0.88, 95% CI [0.66–1.19], P = 0.409), gastrointestinal (OR = 1.19, 95% CI [0.89–1.59], P = 0.241) and hepatic (OR = 1.04, 95% CI [0.83–1.31], P = 0.734) complications, as well as perioperative mortality (OR = 1.79, 95% CI [0.88–3.64], P = 0.108), 5-year DFS (HR = 1.26, 95% CI [0.96–1.66], P = 0.098) and 5-year OS (HR = 1.13, 95% CI [0.95–1.34], P = 0.164). Lower intraoperative blood loss (SMD = − 0.39, 95% CI [− 0.60 to − 0.18], P < 0.001) and shorter total hospital stay (WMD = − 5.43, 95% CI [− 7.29 to − 3.58], P < 0.001) were observed in the simultaneous-resection group versus the staged group. Conclusions Simultaneous resection is safe and effective for SCLM patients. The long-term prognosis is equivalent to that of the traditional staged resection. Correct selection of resectable SCLM patients for the simultaneous resection of the primary tumour and liver metastases can be the first choice. Owing to the potential heterogeneity, more RCTs should be included to verify our conclusions.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and long-term prognosis of simultaneous versus staged resection in synchronous colorectal cancer with liver metastasis: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Currently, a total of four OV products have been approved for marketing: Rigvir (SND005), Oncorine (H101), Imlygic (Talimogene laherparepvec, T-VEC) and Delytact (teserpaturev/G47Δ). Rigvir is an unmodified enteric cytopathic human orphan virus type 7 (ECHO-7), approved for the treatment of melanoma [306][307][308][309][310][311] in Latvia in 2004, 312 making it the first approved oncolytic drug. Later in 2006, the adenovirus-H101 was approved in China, 13 for squamous cell cancer of head and neck or esophagus.…”

Section: Clinical Trials Of Ovsmentioning

confidence: 99%

Oncolytic virotherapy: basic principles, recent advances and future directions

Lin

Shen

Liang

2023

Sig Transduct Target Ther

114

View full text Add to dashboard Cite

Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they are generally considered to have direct oncolysis and cancer immune effects. With the progress in genetic engineering technology, OVs have been adopted as versatile platforms for developing novel antitumor strategies, used alone or in combination with other therapies. Recent studies have yielded eye-catching results that delineate the promising clinical outcomes that OVs would bring about in the future. In this review, we summarized the basic principles of OVs in terms of their classifications, as well as the recent advances in OV-modification strategies based on their characteristics, biofunctions, and cancer hallmarks. Candidate OVs are expected to be designed as “qualified soldiers” first by improving target fidelity and safety, and then equipped with “cold weapons” for a proper cytocidal effect, “hot weapons” capable of activating cancer immunotherapy, or “auxiliary weapons” by harnessing tactics such as anti-angiogenesis, reversed metabolic reprogramming and decomposing extracellular matrix around tumors. Combinations with other cancer therapeutic agents have also been elaborated to show encouraging antitumor effects. Robust results from clinical trials using OV as a treatment congruously suggested its significance in future application directions and challenges in developing OVs as novel weapons for tactical decisions in cancer treatment.

show abstract

“…The oncolytic potential of the present ECHO-7 virus strain has been observed in several malignancies, including melanoma cell lines [ 89 ]. Therefore, the experiments were extended to examine the effect on the cell viability of cytolytic ECHO-7 virus strain on UM cell lines, and out of the seven cell lines tested, only 3 UM cell lines were able to be successfully propagated in the laboratory [ 90 ].…”

Section: Primary Tumor Treatmentmentioning

confidence: 99%

New Treatment Horizons in Uveal and Cutaneous Melanoma

Brănişteanu,

Porumb-Andrese,

Porumb

et al. 2023

Life

View full text Add to dashboard Cite

Melanoma is a complex and heterogeneous malignant tumor with distinct genetic characteristics and therapeutic challenges in both cutaneous melanoma (CM) and uveal melanoma (UM). This review explores the underlying molecular features and genetic alterations in these melanoma subtypes, highlighting the importance of employing specific model systems tailored to their unique profiles for the development of targeted therapies. Over the past decade, significant progress has been made in unraveling the molecular and genetic characteristics of CM and UM, leading to notable advancements in treatment options. Genetic mutations in the mitogen-activated protein kinase (MAPK) pathway drive CM, while UM is characterized by mutations in genes like GNAQ, GNA11, BAP1, EIF1AX, and SF3B1. Chromosomal aberrations, including monosomy 3 in UM and monosomy 10 in CM, play significant roles in tumorigenesis. Immune cell infiltration differs between CM and UM, impacting prognosis. Therapeutic advancements targeting these genetic alterations, including oncolytic viruses and immunotherapies, have shown promise in preclinical and clinical studies. Oncolytic viruses selectively infect malignant cells, inducing oncolysis and activating antitumor immune responses. Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic virus for CM treatment, and other oncolytic viruses, such as coxsackieviruses and HF-10, are being investigated. Furthermore, combining oncolytic viruses with immunotherapies, such as CAR-T cell therapy, holds great potential. Understanding the intrinsic molecular features of melanoma and their role in shaping novel therapeutic approaches provides insights into targeted interventions and paves the way for more effective treatments for CM and UM.

show abstract

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

Cited by 7 publications

References 14 publications

Safety and long-term prognosis of simultaneous versus staged resection in synchronous colorectal cancer with liver metastasis: a systematic review and meta-analysis

Safety and long-term prognosis of simultaneous versus staged resection in synchronous colorectal cancer with liver metastasis: a systematic review and meta-analysis

Oncolytic virotherapy: basic principles, recent advances and future directions

New Treatment Horizons in Uveal and Cutaneous Melanoma

Contact Info

Product

Resources

About